Skandinaviska Enskilda Banken Ab (Publ) Crinetics Pharmaceuticals, Inc. Transaction History
Skandinaviska Enskilda Banken Ab (Publ)
- $21.6 Billion
- Q4 2024
A detailed history of Skandinaviska Enskilda Banken Ab (Publ) transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Skandinaviska Enskilda Banken Ab (Publ) holds 18,117 shares of CRNX stock, worth $637,899. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,117Holding current value
$637,899% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CRNX
# of Institutions
248Shares Held
90MCall Options Held
22.4KPut Options Held
23.4K-
Vanguard Group Inc Valley Forge, PA9.09MShares$320 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.95MShares$245 Million0.07% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$219 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.14MShares$216 Million3.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.41MShares$191 Million0.03% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.89B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...